Oruen

22/07/2026

🧠 Today, on World Brain Day, we celebrate the incredible progress being made in brain health and the people driving it forward.

From pioneering research and innovative treatments to the dedication of healthcare professionals, researchers and patient advocates, every advancement brings us one step closer to improving the lives of those affected by neurological conditions.

At Oruen, we are proud to share the latest developments in neurology, helping connect the global community with the science, innovation and clinical insights shaping the future of brain health.

Together, let's continue to raise awareness, inspire collaboration and champion better brain health for everyone.

💙 Join us in celebrating World Brain Day.

27/05/2026

Complex aneurysm cases demand precision, confidence, and the right technology.

In this new case-based video, Dr Sándor Nardai shares his experience using pCONUS 2 in the treatment of two highly complex basilar tip aneurysms at Semmelweis University.

Serving over 4.5 million people across central Hungary, the neurointerventional team discusses why pCONUS 2 was selected for these challenging wide-neck aneurysms, and how the device supported effective neck remodelling while maintaining procedural safety.

The video also highlights the value of advanced procedural planning with Sim&Cure technology, particularly in a patient with severe renal insufficiency where minimising contrast exposure was essential.

A powerful real-world example of how pCONUS 2 continues to support safe, reliable, and effective aneurysm treatment strategies in complex neurovascular anatomy.

Watch here: https://oruen.com/home-video/why-i-use-pconus-dr-sandor-nardai-wallaby-phenox

 In this insightful case-based video, Dr Sándor Nardai shares his experience using the pCONUS 2 by WallabyPhenox in the treatment of two highly complex basilar aneurysm cases. As the leading neurointerventional centre for the central Hungarian region, serving more than 4.5 million people, the...

11/04/2026

Today is World Parkinson’s Day.

A moment to pause, reflect, and recognise the reality of a condition that affects more than 10 million people worldwide—and over 150,000 individuals here in the UK alone. Parkinson’s is now the fastest-growing neurological condition in the world, yet it remains widely misunderstood.

Parkinson’s is not just a tremor. It is a complex, progressive condition with over 40 possible symptoms—many of them invisible. It impacts movement, mood, cognition, and quality of life, not only for those diagnosed but for families, carers, and entire communities.

That’s why awareness matters.

World Parkinson’s Day is more than a date in the calendar. It is a global call to:

• Shine a light on the lived experience of Parkinson’s
• Break down stigma and misunderstanding
• Advocate for better care, research, and earlier diagnosis
• Unite a global community working towards change

At Oruen CNS, we believe that education and storytelling are powerful tools in that mission.

Through our movement disorders content and our Parkinson’s-focused podcast series, we aim to amplify expert voices, share real patient experiences, and drive meaningful conversations that push the field forward.

Explore more:
🔗 Movement disorders hub: https://oruen.com/category/neurology/movement-disorders

🎧 Podcasts: https://oruen.com/category/podcasts

Because awareness is not just about understanding Parkinson’s—it’s about changing the future for everyone living with it.

27/03/2026

🧠 Oruen CNS Weekly Roundup: The Latest in CNS Medicine 🧠

The CNS field continues to evolve rapidly, with new developments emerging across psychiatry, neurology, and interventional neuroscience.

This week’s highlights include:

• Depression – psilocybin-assisted therapy shows clinical benefit
• Schizophrenia – novel muscarinic-targeting treatments
• Alzheimer’s disease – semaglutide explored in early disease
• Migraine – optimising preventive treatment strategies
• Stroke – OCEANIC-STROKE trial insights
• Multiple sclerosis – positive Phase 3 results for fenebrutinib
• Neuroradiology – AI improving early prediction of outcomes

Together, these developments reflect the breadth of innovation across CNS medicine.

Explore the full roundup here:
https://oruen.com/latest-news/oruen-cns-weekly-roundup-3

20/03/2026

🧠 Oruen CNS Weekly Roundup: The Latest in CNS Medicine 🧠

The CNS field continues to evolve rapidly, with new developments emerging across both neurology and psychiatry.

This week’s highlights include:

• Depression – next-generation rapid-acting antidepressants

• ADHD – digital therapeutics and cognitive interventions

• Sleep disorders – advances in insomnia treatment and neurobiology

• Alzheimer’s disease – blood-based biomarkers improving early diagnosis

• Migraine – continued evolution of CGRP-targeting therapies

• Neuro-oncology – targeted and immunotherapy approaches in glioblastoma

• Neurosurgery – minimally invasive and image-guided techniques

• Pain – growing role of neuromodulation in chronic pain management

Together, these developments reflect the breadth of innovation across CNS medicine.

Explore the full roundup here:

https://oruen.com/latest-news/oruen-cns-weekly-roundup-2

🧠 Oruen CNS Weekly Roundup: The Latest in CNS Medicine 🧠 The field of CNS medicine continues to advance across a wide range of neurological and psychiatric conditions. This week’s roundup highlights new research spanning psychiatry, neurodegeneration, neuro-oncology, headache, and interventi...

18/03/2026

🧠 Brain Awareness Week 2026 🧠

The brain is at the centre of everything we do — yet awareness, education, and access to knowledge in CNS still have a long way to go.

Brain Awareness Week is a global initiative bringing together researchers, clinicians, institutions, and organisations worldwide to increase understanding of the brain and the impact of neuroscience on everyday life. (Dana Foundation)

This week highlights not only scientific progress — but the importance of sharing that knowledge to improve patient care, outcomes, and global understanding.

🔗 Learn more about the global campaign:

https://cutt.ly/LtUTpXm5

🔗 See how leading institutions are contributing:

https://cutt.ly/ptUTdulI

🔗 Explore European neuroscience outreach:

https://cutt.ly/ntUTp7UO

At Oruen, we are proud to support this mission by:

🔹 Connecting over 40,000 healthcare professionals across CNS

🔹 Amplifying expert voices in neurology, psychiatry, and neurodevelopment

🔹 Bridging the gap between research and real-world clinical practice

🔹 Delivering high-quality, accessible medical education

🌐 Explore more: https://oruen.com

Because better awareness leads to better understanding — and better understanding leads to better outcomes.

16/03/2026

🧠 The Big Picture of ADHD & Individualising Treatment | CME Accredited 🧠

ADHD diagnosis and treatment have changed dramatically over the past two decades. While increased awareness has improved access to care, clinicians now face new challenges including rising diagnostic demand, service pressures, and evolving expectations from patients and families.

In this expert roundtable, leading European specialists explore both the broader landscape of ADHD and the practical realities of delivering personalised treatment in clinical practice:

• Prof. Sven Bölte — Karolinska Institute, Sweden

• Dr Maite Ferrin — Haringey NHS Partnership & UCL, UK

• Prof. Tobias Banaschewski — Central Institute of Mental Health, Heidelberg University, Germany

The discussion is presented across two educational sessions combining clinical evidence, expert experience, and real-world insight.

▶️ Part 1: The Big Picture of ADHD

Exploring the evolving landscape of ADHD across Europe, including:

• ADHD as a dimensional neurodevelopmental condition

• Rising diagnostic demand and assessment challenges

• Neurodiversity and its impact on clinical practice

• Healthcare system pressures and treatment pathways

▶️ Part 2: Individualising ADHD Treatment

Focusing on personalised clinical management:

• Multimodal treatment strategies

• Pharmacological and non-pharmacological approaches

• Patient and family perspectives

• ADHD heterogeneity and comorbidities

• Barriers to care and service fragmentation

• The future of ADHD treatment — precision medicine and digital innovation

🎓 CME Accredited

The European Accreditation Committee in CNS (EACIC) has granted 1 CME credit to this programme.

👉 Watch the programme and learn how to claim CME credits: https://oruen.com/home-video/the-big-picture-of-adhd-individualising-treatment-cme-accredited-2

Event Code: ORUEN26

Deadline to claim CME: 30 September 2026

This roundtable discussion was supported by Neuraxpharm.

13/03/2026

🧠 Oruen CNS Weekly Roundup 🧠

The latest developments in CNS medicine highlight the breadth of innovation across neurology.

This week’s roundup includes:

• New insights from the CHOICE-2 stroke thrombectomy trial
• The GRASSROOT trial investigating next-generation thrombectomy devices
• Research exploring expanded thrombectomy treatment windows
• Emerging stem-cell and regenerative therapies in Parkinson’s disease
• Progress in iPSC-derived dopaminergic treatments
• New therapeutic developments including tavapadon and bemdaneprocel
• Promising genetic therapies for rare epilepsies, including Dravet syndrome and STXBP1 encephalopathy

Explore the full roundup here:
https://oruen.com/latest-news/oruen-cns-weekly-roundup

26/02/2026

📘 Oruen – The CNS Journal Volume 11 | Issue 2 (February 2026) is now live!

This latest issue brings together expert perspectives, congress highlights, infographics, and review articles covering key developments across neurology — from Parkinson’s disease and stroke care to Alzheimer’s research and global health equity.

🔹 Special Reports:

EANS2025 Vienna Congress – A Congress for the History Books — European Association of Neurosurgical Societies (EANS)

Highlights from the 35th Alzheimer Europe Conference — Alzheimer Europe

The cost of Parkinson’s revealed in new Europe-wide workplace survey of people living with Parkinson’s — Parkinson's Europe

14th World Congress for Neurorehabilitation (WCNR 2026), Daegu, Republic of Korea — World Federation of Neuro Rehabilitation

🔹 Infographics:

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson’s Disease — AbbVie

🔹 Review Articles:

Saving Time in Acute Stroke Treatment – ESMINT 17th Congress Highlights — Marios Psychogios, Prof. Dr. - Siemens Healthineers

From Alteplase to Tenecteplase for Acute Ischaemic Stroke: A Catalyst for Stroke Care Improvement — Martin James et al. Boehringer Ingelheim

Improving Stroke Care in Low- and Middle-Income Countries: Challenges, Opportunities, and Strategies for Global Equity — Jayden Asher

Advances in Alzheimer’s Disease in Europe: Recent Trial Breakthroughs and Emerging Treatments — Jayden Asher

Explore the full e-book issue here:

📖 https://oruen.com/Journal/Volume11Issue2/

19/02/2026

🎥 Prolonged Seizures & Status Epilepticus: When to Act and How to Use Rescue Medication

In this expert discussion, Professor Matthew Walker (UCL Queen’s Square Institute of Neurology) outlines when a seizure should be considered prolonged, who is most at risk of status epilepticus, and why rapid, adequately dosed rescue medication is critical.

He explores practical time thresholds, seizure clustering, the evidence behind benzodiazepines, and the importance of having a clear, written rescue plan in place for every person with epilepsy.

Status epilepticus carries significant morbidity and mortality — early recognition and timely intervention can be lifesaving.

Watch the full video here: https://oruen.com/home-video/prolonged-seizures-status-epilepticus-when-to-act-and-how-to-use-rescue-medication

Special thanks to Neuraxpharm for supporting this video.

 This video was supported by Neuraxpharm In this expert video, Professor Matthew Walker (UCL Queen’s Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London) provides a comprehensive overview of prolonged seizures and the prevention of status epil...